Because guidance and enforcement priorities may continue evolving, clinics should regularly monitor FDA communications and consult qualified legal, regulatory, and healthcare professionals when evaluating their GLP-1 programs
Food supplement, with sweeteners
Collaboration with state regulators and ongoing market surveillance ensure robust enforcement to prevent unsafe or fraudulent GLP-1 drugs from reaching consumers
The de novo biosynthesis of sphingolipids, catalyzed by serine palmitoyltransferase, connects serine and mitochondrial alanine metabolism to membrane lipid diversity, a mechanism that could be exploited to induce tumor cell death under metabolic stress, such as in an amino acid-deprived microenvironment [126]
GLP-1 receptor agonists slow gastric emptying and reduce appetite by acting on brain receptors, requiring smaller meal portions and slower eating pace